Official websites use. Share sensitive information only on official, secure websites. Correspondence: damien. Prostate cancer PCa is the second most frequent cancer and the fifth leading cause of cancer death in men worldwide. If local PCa presents a favorable prognosis, available treatments for advanced PCa display limiting benefits due to therapeutic resistances. Nucleolin NCL is a ubiquitous protein involved in numerous cell processes, such as ribosome biogenesis, cell cycles, or angiogenesis.
NCL is overexpressed in several tumor types in which it has been proposed as a diagnostic and prognostic biomarker. Nevertheless, little data are available concerning its expression in patient tissues. Here, we investigated the expression of NCL using a new cohort from Mondor Hospital and data from published cohorts. Results were then compared with NCL expression using in vitro models. NCL was overexpressed in PCa tissues compared to the normal tissues, but no prognostic values were demonstrated.
Nine genes were highly co-expressed with NCL in patient tissues and tumor prostate cell lines. Our data demonstrate that NCL is an interesting diagnostic biomarker and propose a signature of genes co-expressed with NCL. Prostate cancer PCa is currently the second most common malignancy and the fifth leading cause of cancer death worldwide with 1.
While PCa is frequently curable when it is diagnosed early, advanced PCa represents a significant source of mortality and morbidity. As prostate tumor cells are dependent on androgens for their survival and growth, the gold standard therapy is then androgen deprivation therapy ADT.
Unfortunately, after an initial efficient clinical response, tumors relapse within 1β3 years, leading to castrate-resistant prostate cancer CRPC. Since the last decade, new therapies are available for CRPCs, including new androgen receptor pathway inhibitors ARPIs, such as the abiraterone acetate, enzalutamide, apalutamide, or darolutamide , chemotherapies docetaxel and cabazitaxel , and radionuclides radium or Lutenium [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ].
